N Collinson1, J R Atack, P Laughton, G R Dawson, D N Stephens. 1. Merck Sharp and Dohme Research Laboratories, The Neuroscience Research Centre, Terlings Park, Harlow,, Essex, CM20 2QR, UK. neil_collinson@fsmail.net
Abstract
RATIONALE: Compounds selective for the GABAA receptors containing an alpha5 subunit have been reported to enhance performance in the hippocampally mediated delayed-matching-to-position version of the Morris water maze, in which reduction in the time required to find a hidden platform relative to an initial trial is used as an index of learning and memory. OBJECTIVE: In the present study, we have used one such compound, alpha5IA-II, to examine whether these effects occur during the encoding, consolidation or recall phases of this paradigm. METHODS: alpha5IA-II was administered in the absence or presence of the benzodiazepine site antagonist flumazenil, so as to limit its action to periods associated with encoding, consolidation and recall. Drug doses and timings of administrations were defined using occupancy data derived from an in vivo [3H]flumazenil binding assay. Similar experiments were carried out to study the memory-disruptive properties of chlordiazepoxide (CDP). RESULTS: The trial 1 to trial 2 difference was increased when alpha5IA-II was given before either trial 1 or trial 2, indicating an effect on the encoding and recall phases, respectively, of learning and memory. Conversely, alpha5IA-II had no effect on performance when given immediately after trial 1, suggesting that it had no effect on the consolidation phase. In contrast to the facilitation of performance produced by the alpha5-selective inverse agonist alpha5IA-II given during the encoding and recall but not the consolidation phase, the non-selective agonist CDP impaired performance when given during the encoding and recall phases, whilst having no effect on the consolidation phase. CONCLUSIONS: These data further highlight the cognition-enhancing properties of GABAA alpha5-selective inverse agonists and define the functional specificity of these effects in terms of encoding and recall processes in the Morris water maze.
RATIONALE: Compounds selective for the GABAA receptors containing an alpha5 subunit have been reported to enhance performance in the hippocampally mediated delayed-matching-to-position version of the Morris water maze, in which reduction in the time required to find a hidden platform relative to an initial trial is used as an index of learning and memory. OBJECTIVE: In the present study, we have used one such compound, alpha5IA-II, to examine whether these effects occur during the encoding, consolidation or recall phases of this paradigm. METHODS: alpha5IA-II was administered in the absence or presence of the benzodiazepine site antagonist flumazenil, so as to limit its action to periods associated with encoding, consolidation and recall. Drug doses and timings of administrations were defined using occupancy data derived from an in vivo [3H]flumazenil binding assay. Similar experiments were carried out to study the memory-disruptive properties of chlordiazepoxide (CDP). RESULTS: The trial 1 to trial 2 difference was increased when alpha5IA-II was given before either trial 1 or trial 2, indicating an effect on the encoding and recall phases, respectively, of learning and memory. Conversely, alpha5IA-II had no effect on performance when given immediately after trial 1, suggesting that it had no effect on the consolidation phase. In contrast to the facilitation of performance produced by the alpha5-selective inverse agonist alpha5IA-II given during the encoding and recall but not the consolidation phase, the non-selective agonist CDP impaired performance when given during the encoding and recall phases, whilst having no effect on the consolidation phase. CONCLUSIONS: These data further highlight the cognition-enhancing properties of GABAA alpha5-selective inverse agonists and define the functional specificity of these effects in terms of encoding and recall processes in the Morris water maze.
Authors: G Riedel; J Micheau; A G Lam; E L Roloff; S J Martin; H Bridge; L de Hoz; B Poeschel; J McCulloch; R G Morris Journal: Nat Neurosci Date: 1999-10 Impact factor: 24.884
Authors: Rebecca Dias; Wayne F A Sheppard; Rosa L Fradley; Elizabeth M Garrett; Joanna L Stanley; Spencer J Tye; Simon Goodacre; Rachael J Lincoln; Susan M Cook; Rachel Conley; David Hallett; Alexander C Humphries; Sally A Thompson; Keith A Wafford; Leslie J Street; J Luis Castro; Paul J Whiting; Thomas W Rosahl; John R Atack; Ruth M McKernan; Gerard R Dawson; David S Reynolds Journal: J Neurosci Date: 2005-11-16 Impact factor: 6.167
Authors: F Crestani; R Keist; J-M Fritschy; D Benke; K Vogt; L Prut; H Blüthmann; H Möhler; U Rudolph Journal: Proc Natl Acad Sci U S A Date: 2002-06-25 Impact factor: 11.205
Authors: Paul L Soto; Nancy A Ator; Sundari K Rallapalli; Poonam Biawat; Terry Clayton; James M Cook; Michael R Weed Journal: Neuropsychopharmacology Date: 2013-05-31 Impact factor: 7.853
Authors: Hui Shen; Nicole Sabaliauskas; Ang Sherpa; André A Fenton; Armin Stelzer; Chiye Aoki; Sheryl S Smith Journal: Science Date: 2010-03-19 Impact factor: 47.728
Authors: K Hoestgaard-Jensen; R M O'Connor; N O Dalby; C Simonsen; B C Finger; A Golubeva; H Hammer; M L Bergmann; U Kristiansen; P Krogsgaard-Larsen; H Bräuner-Osborne; B Ebert; B Frølund; J F Cryan; A A Jensen Journal: Br J Pharmacol Date: 2013-10 Impact factor: 8.739
Authors: Chelcie F Heaney; Monica M Bolton; Andrew S Murtishaw; Jonathan J Sabbagh; Christy M Magcalas; Jefferson W Kinney Journal: Neurobiol Learn Mem Date: 2012-09-23 Impact factor: 2.877
Authors: John R Atack; Wai-Si Eng; Ray E Gibson; Christine Ryan; Barbara Francis; Bindi Sohal; Gerard R Dawson; Richard J Hargreaves; H Donald Burns Journal: Br J Pharmacol Date: 2009-04-30 Impact factor: 8.739
Authors: Miroslav M Savić; Marija M Milinković; Sundari Rallapalli; Terry Clayton; Sroan Joksimović; Michael Van Linn; James M Cook Journal: Int J Neuropsychopharmacol Date: 2009-03-06 Impact factor: 5.176